MDPI and ACS Style
Park, Y.S.; Kang, S.B.; Marchelletta, R.R.; Penrose, H.M.; Ruiter-Visser, R.; Jung, B.; Docherty, M.J.; Boland, B.S.; Sandborn, W.J.; McCole, D.F.
The ClC-2 Chloride Channel Activator, Lubiprostone, Improves Intestinal Barrier Function in Biopsies from Crohn’s Disease but Not Ulcerative Colitis Patients. Pharmaceutics 2023, 15, 811.
https://doi.org/10.3390/pharmaceutics15030811
AMA Style
Park YS, Kang SB, Marchelletta RR, Penrose HM, Ruiter-Visser R, Jung B, Docherty MJ, Boland BS, Sandborn WJ, McCole DF.
The ClC-2 Chloride Channel Activator, Lubiprostone, Improves Intestinal Barrier Function in Biopsies from Crohn’s Disease but Not Ulcerative Colitis Patients. Pharmaceutics. 2023; 15(3):811.
https://doi.org/10.3390/pharmaceutics15030811
Chicago/Turabian Style
Park, Young Su, Sang Bum Kang, Ronald R. Marchelletta, Harrison M. Penrose, Roos Ruiter-Visser, Barbara Jung, Michael J. Docherty, Brigid S. Boland, William J. Sandborn, and Declan F. McCole.
2023. "The ClC-2 Chloride Channel Activator, Lubiprostone, Improves Intestinal Barrier Function in Biopsies from Crohn’s Disease but Not Ulcerative Colitis Patients" Pharmaceutics 15, no. 3: 811.
https://doi.org/10.3390/pharmaceutics15030811